A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback